Maintaining cardiovascular health in patients with mixed dyslipidemia: Optimizing the management of hypertriglyceridemia and non-HDL cholesterol

Journal of Managed Care Pharmacy

Volumn 15, Issue 1 SUPPL. C, 2009, Pages

  Ito, Matthew K ^a   McKenney, James M ^b,c   Brinton, Eliot A ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c National Clinical Research Inc   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RETINOID DERIVATIVE; STEROID; TAMOXIFEN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEALTH CARE NEED; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 60849083548     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.s1-c.1     Document Type: Review

References (37)

1. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clin Ther. 2008;30(2):294-306.
2. American Heart Association. Triglycerides. What are triglycerides? Available at: Http://www.americanheart.org/ presenter.jhtml?identifier=4778. Accessed June 11, 2008.
3. National Institutes of Health. Medline Medical Dictionary: Cholesterol. http://www.nlm.nih.gov/medlineplus/mplusdietionary.html. Accessed June 11, 2008.
4. Segrest JP, Garber DW, Brouillette CG, Harvey SC, Anantharamaiah GM. The amphipathic alpha helix: A multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem. 1994;45:303-69.
5. Garcia-Calvo M, Lisnock J, Bull HG, et al., The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102(23):8132-37.
6. Goldstein JL, Brown MS. Molecular medicine. The cholesterol quartet. Science. 2001;292(5520):1310-12.
7. Genest J. Lipoprotein disorders and cardiovascular risk. J Inherit Metab Dis. 2003;26(2-3):267-87.
8. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation. 2007;116(16):1832-44.
9. Shepherd J. The role of the exogenous pathway in hypercholesterolaemia. Eur Heart J. 2001;3(suppl E):E2-E5.
10. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586-92.
11. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front Biosci. 2001;6:D332-D354.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
13. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-07.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-89.
15. Sever PS, Dahlöf B, Poulter NR, et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-58.
16. Calhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96.
17. Kannel WB. Importance of hypertension as a major risk factor in cardiovascular disease. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: Physiopathology and Treatment. New York, NY: McGraw-Hill; 1977:888-10.
18. Cromwell WC, Otvos JD, Keyes MJ, et al., LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol. 2007;1(6):583-92.
19. Assmann G, Schulte H, Funke H, Von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8-M14.
20. Weissberg PL, Rudd JH. Atherosclerotic biology and epidemiology of disease. In: Iopol EJ, ed. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:3-14.
21. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother. 2003;4(11):1901-38.
22. Lamarche B, Tchernof A, Moorjani S, et al., Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95(1):69-75.
23. Baylor College of Medicine. Lipids online: Educational resources in atherosclerosis. Available at: Http://www.lipidsonline.org. Accessed June 26, 2008.
24. Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. CMAJ. 2002;167(11):1261-66.
25. Hachem SB, Mooradian AD. Familial dyslipidaemias: An overview of genetics, pathophysiology and management. Drugs. 2006;66(15):1949-69.
26. Dunbar RL, Rader DJ. Demystifying triglycerides: A practical approach for the clinician. Cleve Clin J Med. 2005;72(8):661-66, 670-72, 674-75.
27. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; for the PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 Trial. J Am Coll Cordiol. 2008;51(7):724-30.
28. Grundy SM, Cleeman JI, Daniels SR, et al., Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cordiol. 2006;21(1):1-6.
29. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-59.
30. Isomaa B, Almgren F, Tuomi T, et al., Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-89.
31. Kathiresan S, Otvos JD, Sullivan LM, et al., Increased small low-density lipoprotein particle number: A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113(1):20-29.
32. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Bethesda, MD: National Institutes of Health; 2002. NIH Publication No. 02-5215.
33. Grundy SM, Cleeman JI, Merz CN, et al., for the National Heart, Blood, and Lung Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110(2):227-39.
34. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: An analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cordiol. 2005;45(10):1644-48.
35. LaRosa JC, Grundy SM, Waters DD, et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35.
36. Kris-Etherton PM, Harris WS, Appel LJ; for the American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-57.
37. American Heart Association. Fish and omega-3 fatty acids: AHA recommendation. Available at: Http://www.americanheart.org/ presenter.jhtml?identifier=4632. Accessed June 10, 2008.